Mercialys Valuation
Is MERY undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
5/6Valuation Score 5/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of MERY when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: MERY (€10.91) is trading below our estimate of fair value (€17.07)
Significantly Below Fair Value: MERY is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for MERY?
Key metric: As MERY is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is MERY's PE Ratio? | |
|---|---|
| PE Ratio | 17.2x |
| Earnings | €59.18m |
| Market Cap | €1.02b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 12.8x |
| Enterprise Value/EBITDA | 17.4x |
| PEG Ratio | 1.3x |
Price to Earnings Ratio vs Peers
How does MERY's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 26.5x | ||
FREY Frey | 31.8x | n/a | €912.8m |
CARM Carmila | 45x | 21.6% | €2.4b |
SELER Selectirente | 16.9x | n/a | €362.3m |
LI Klépierre | 12.3x | 9.4% | €8.3b |
MERY Mercialys | 17.2x | 13.5% | €1.0b |
Price-To-Earnings vs Peers: MERY is good value based on its Price-To-Earnings Ratio (17.2x) compared to the peer average (26.5x).
Price to Earnings Ratio vs Industry
How does MERY's PE Ratio compare vs other companies in the European Retail REITs Industry?
| 0 Companies | Price / Earnings | Estimated Growth | Market Cap |
|---|---|---|---|
| 0 Companies | Estimated Growth | Market Cap |
|---|
Price-To-Earnings vs Industry: MERY is good value based on its Price-To-Earnings Ratio (17.2x) compared to the European Retail REITs industry average (22.5x).
Price to Earnings Ratio vs Fair Ratio
What is MERY's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 17.2x |
| Fair PE Ratio | 19.2x |
Price-To-Earnings vs Fair Ratio: MERY is good value based on its Price-To-Earnings Ratio (17.2x) compared to the estimated Fair Price-To-Earnings Ratio (19.2x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | €10.91 | €12.92 +18.4% | 6.1% | €14.50 | €12.50 | n/a | 5 |
| Nov ’25 | €10.69 | €12.92 +20.9% | 6.1% | €14.50 | €12.50 | n/a | 5 |
| Oct ’25 | €12.19 | €12.58 +3.2% | 4.1% | €13.50 | €11.90 | n/a | 5 |
| Sep ’25 | €11.60 | €12.40 +6.9% | 6.8% | €13.50 | €11.10 | n/a | 5 |
| Aug ’25 | €11.78 | €12.40 +5.3% | 6.8% | €13.50 | €11.10 | n/a | 5 |
| Jul ’25 | €10.40 | €11.45 +10.1% | 3.1% | €12.00 | €11.10 | n/a | 4 |
| Jun ’25 | €11.63 | €11.70 +0.6% | 3.1% | €12.10 | €11.20 | n/a | 4 |
| May ’25 | €10.16 | €11.70 +15.2% | 3.1% | €12.10 | €11.20 | n/a | 4 |
| Apr ’25 | €10.79 | €11.70 +8.4% | 3.1% | €12.10 | €11.20 | n/a | 4 |
| Mar ’25 | €10.06 | €11.45 +13.8% | 3.7% | €12.00 | €10.80 | n/a | 4 |
| Feb ’25 | €10.33 | €11.46 +10.9% | 3.3% | €12.00 | €10.80 | n/a | 5 |
| Jan ’25 | €9.95 | €10.50 +5.6% | 13.0% | €12.00 | €8.50 | n/a | 4 |
| Dec ’24 | €9.01 | €10.50 +16.5% | 13.0% | €12.00 | €8.50 | n/a | 4 |
| Nov ’24 | €8.05 | €11.17 +38.8% | 7.6% | €12.00 | €10.00 | €10.69 | 3 |
| Oct ’24 | €8.53 | €11.17 +30.9% | 7.6% | €12.00 | €10.00 | €12.19 | 3 |
| Sep ’24 | €8.50 | €10.57 +24.4% | 16.0% | €12.00 | €8.20 | €11.60 | 3 |
| Aug ’24 | €7.89 | €10.57 +33.9% | 16.0% | €12.00 | €8.20 | €11.78 | 3 |
| Jul ’24 | €8.27 | €9.85 +19.2% | 16.8% | €11.50 | €8.20 | €10.40 | 2 |
| Jun ’24 | €7.51 | €10.85 +44.6% | 6.0% | €11.50 | €10.20 | €11.63 | 2 |
| May ’24 | €9.12 | €10.85 +19.0% | 6.0% | €11.50 | €10.20 | €10.16 | 2 |
| Apr ’24 | €9.41 | €11.35 +20.6% | 1.3% | €11.50 | €11.20 | €10.79 | 2 |
| Mar ’24 | €10.27 | €11.35 +10.5% | 1.3% | €11.50 | €11.20 | €10.06 | 2 |
| Feb ’24 | €10.24 | €10.75 +5.0% | 7.0% | €11.50 | €10.00 | €10.33 | 2 |
| Jan ’24 | €9.77 | €10.75 +10.0% | 7.0% | €11.50 | €10.00 | €9.95 | 2 |
| Dec ’23 | €9.28 | €10.75 +15.8% | 7.0% | €11.50 | €10.00 | €9.01 | 2 |
| Nov ’23 | €8.94 | €10.75 +20.2% | 7.0% | €11.50 | €10.00 | €8.05 | 2 |
Analyst Forecast: Target price is less than 20% higher than the current share price.
Discover undervalued companies
Healthcare Activos Yield SOCIMI
€245.6m
Operates as a real estate investment vehicle that focuses on the healthcare sector in Europe.
MLHAY
€1.41
7D
0%
1Y
4.4%
Faifey Invest Socimi
€98.7m
Invests in real estate assets in Spain.
MLECE
€19.50
7D
0%
1Y
20.4%
Paref
€60.9m
Owns and manages business real estate located primarily in the Paris region.
PAR
€40.40
7D
1.0%
1Y
-15.5%